These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 26395531

  • 1. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W, Louis E, Danese S.
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K, Molnár T.
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J, Kaasen Jørgensen K.
    Dig Dis; 2017 Feb; 35(1-2):83-90. PubMed ID: 28147374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.